Business
Be The Match BioTherapies® and Atara Biotherapeutics Announce Multi-Year Partnership Extension
Relationship Will Leverage Be The Match BioTherapies’ Expertise and Expansive Donor Registry to Provide Healthy Donor Cells in Support of Atara’s Allogeneic
About this update from Atara Biotherapeutics, Inc.
[{"type":"text","content":"\nRelationship Will Leverage Be The Match BioTherapies’ Expertise and Expansive Donor Registry to Provide Healthy Donor Cells in Support of Atara’s Allogeneic T-cell Platform\n\n MINNEAPOLIS & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nBe The Match BioTherapies and Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced an extension of their collaboration to provide high-quality healthy donor cells for Atara’s off-the-shelf T-cell immunotherapy platform for patients with cancer and autoimmune diseases.\n\nThis multi-year partnership leverages the capabilities of Be The Match BioTherapies to source healthy donor cells from the Be The Match Registry® with over 22 million genetically diverse human leukocyte antigen (HLA) immune profiles.\n\n“Atara and Be The Match BioTherapies share an aspiration to serve every patient, and this partnership will allow us to deliver treatments to the patient populations that our organization was founded to help,” said Chris McClain, Senior Vice President, Sales and Business Development at Be The Match BioTherapies. “We are proud to provide a consistent supply of high-quality, compliant, and consented HLA-specific starting material to support Atara’s tabelecleucel (tab-cel®) program, including the ongoing Phase 3 ALLELE study, and its other pipeline candidates.”\n\nSince 2016, Be The Match BioTherapies has been a strategic supplier to Atara by providing the cellular starting material, peripheral blood mononuclear cells, from healthy donors with targeted HLA haplotypes for further manufacture and cryopreservation as inventory ready to be delivered to patients in need in just a few days. Cutting-edge bioinformatic insights into HLA genetics have supported Atara’s clinical programs by ensuring that for each product, an inventory of different manufactured lots is available for partial matching to patient HLA profiles to support efficacy and safety. Be The Match BioTherapies’ regulatory expertise ensures the collection of donor cells that meet FDA and varying international regulations, broadening the potential use of the therapies.\n\n“With our recent EU regulatory marketing authorization application submission for tabelecleucel, the first-ever off-the-shelf allogeneic T-cell therapy to be reviewed by any regulatory agency in the world, we are one step closer to bringing this potentially transfor...